Predicted Indirectly ReCognizable HLA Epitopes (PIRCHE) Are Associated with Poorer Outcome after Single Mismatch Unrelated Donor Stem Cell Transplantation: A Study of the Cooperative Transplant Study Group (KTS) of the German Group for Bone Marrow and Stem Cell Transplantation (DAG-KBT).
Allogeneic hematopoietic stem cell transplantation
Outcome
PIRCHE
Journal
Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie
ISSN: 1660-3796
Titre abrégé: Transfus Med Hemother
Pays: Switzerland
ID NLM: 101176417
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
29
04
2019
accepted:
21
07
2019
entrez:
14
12
2019
pubmed:
14
12
2019
medline:
14
12
2019
Statut:
ppublish
Résumé
There is no established standard for selection of mismatched unrelated donors. Indirect recognition of HLA mismatches can be predicted using the model of "Predicted Indirectly ReCognizable HLA Epitopes" (PIRCHE). We performed a multicenter retrospective study evaluating the impact PIRCHE on outcome after allogeneic stem cell transplantation (allo-HSCT) from single mismatched (HLA 9/10 matched) unrelated donors. The study cohort included 424 adult recipients of HLA 9/10 matched unrelated donor transplants (9/10 MUD), treated for AML or MDS at 6 transplant centers across Germany. Detection of PIRCHE was associated with lower overall survival (OS) (47 vs. 57%,
Identifiants
pubmed: 31832062
doi: 10.1159/000502389
pii: tmh-0046-0370
pmc: PMC6876613
doi:
Types de publication
Journal Article
Langues
eng
Pagination
370-375Informations de copyright
Copyright © 2019 by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
This work was supported by a research grant from PIRCHE AG to the University Medical Center Hamburg. All authors do not have any conflicting interest with PIRCHE AG or the PIRCHE algorithm and declare no further conflicts of interest.
Références
Blood. 2007 Dec 15;110(13):4576-83
pubmed: 17785583
Biol Blood Marrow Transplant. 2011 Jun;17(6):885-92
pubmed: 20870028
Blood. 2004 Oct 1;104(7):1923-30
pubmed: 15191952
Blood. 2013 Oct 31;122(18):3220-9
pubmed: 24046013
Am J Med. 1980 Aug;69(2):204-17
pubmed: 6996481
Bone Marrow Transplant. 1995 Jun;15(6):825-8
pubmed: 7581076
Transplantation. 2008 Mar 15;85(5):667-9
pubmed: 18337656
J Immunol. 2012 Feb 15;188(4):1868-73
pubmed: 22262656
Front Immunol. 2014 May 12;5:210
pubmed: 24860572
Blood. 2007 Oct 1;110(7):2235-41
pubmed: 17554059
Biol Blood Marrow Transplant. 2012 May;18(5):739-46
pubmed: 21963622
J Immunol Res. 2014;2014:159479
pubmed: 24868561
Lancet Oncol. 2012 Apr;13(4):366-74
pubmed: 22340965
Blood. 2012 Oct 4;120(14):2918-24
pubmed: 22829628
Biol Blood Marrow Transplant. 2014 Nov;20(11):1705-10
pubmed: 24980111
Hum Immunol. 2013 Mar;74(3):290-6
pubmed: 23232063
Blood. 2014 Oct 16;124(16):2596-606
pubmed: 25161269
Biol Blood Marrow Transplant. 2009 Aug;15(8):971-81
pubmed: 19589487
N Engl J Med. 2014 Jul 24;371(4):339-48
pubmed: 25054717
Blood. 2009 Aug 13;114(7):1437-44
pubmed: 19515726
Blood. 2014 Feb 20;123(8):1270-8
pubmed: 24408320
Blood. 2004 Feb 15;103(4):1417-24
pubmed: 14576061